Key facts
- It has raised $11.5M; the latest was Later Stage VC in May 2025.
- Notable investors include Guangzhou Yuexiu Industrial Investment Fund Management, Guangzhou Jinkong Fund, Cherami Investment Group, Guangzhou Financial Holdings, Guangzhou Science and Technology Financial Innovation Investment Holding — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Enkang Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Enkang Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enkang Pharmaceutical
Developer and manufacturer of therapeutic compounds and delivery systems intended for oncology and respiratory disease treatment. The company offers a novel DNA replication initiation protein (DRIP) inhibition mechanism, proprietary lipid-based inhalation formulations, and nanoparticle encapsulation technologies, serving pharmaceutical and clinical research markets to pursue targeted, low-toxicity therapies with enhanced bioavailability, improved tissue selectivity, and compatibility with international multi-center clinical trial standards.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Website
- ek-pharma.com/
- Ownership
- Privately Held (backing)
Enkang Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enkang Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enkang Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.